Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data Meeting Abstract
| Authors: | Friedlander, T. W.; Milowsky, M. I.; O'Donnell, P. H.; Petrylak, D. P.; Hoimes, C. J.; Flaig, T. W.; Mar, N.; Moon, H. H.; McKay, R. R.; Bilen, M. A.; Borchiellini, D.; Iafolla, M.; Carret, A. S.; Yu, Y.; Guseva, M.; Kataria, R. S.; Rosenberg, J. E. |
| Abstract Title: | Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.4568 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 4568 -- This meeting was also held virtually -- Source: Cinahl |
